Adenomyosis risk factor
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have sufficient information from the textbooks. Here is a comprehensive summary of adenomyosis risk factors:
Adenomyosis — Risk Factors
Adenomyosis is defined as the presence of endometrial glands and stroma within the myometrium. Its exact pathogenesis is not fully understood, but several risk factors have been consistently identified.
Demographic & Reproductive Risk Factors
| Factor | Detail |
|---|---|
| Age | Most common in the 4th–5th decades of life (perimenopausal women), with increasing prevalence in later reproductive years |
| Multiparity | Found more commonly in multiparous patients than nulliparous patients — prior uterine surgery or trauma during delivery may allow endometrial cells to infiltrate the myometrium |
| Reproductive years | Prevalence estimated at ~30% of patients of reproductive age |
Hormonal & Estrogenic Factors
- Estrogen dependence: Adenomyosis, like endometriosis, is an estrogen-dependent condition. Prolonged estrogen stimulation is considered a key driver.
- It shares pathophysiological mechanisms with endometriosis and uterine leiomyomas, both of which are also hormone-sensitive.
Uterine Structural Factors
- Prior uterine surgery (e.g., cesarean section, D&C, myomectomy): Disruption of the junctional zone (the boundary between endometrium and myometrium) is thought to facilitate invasion of endometrial tissue into the myometrium.
- Co-existing uterine leiomyoma: Adenomyosis often coexists with fibroids, suggesting shared hormonal or inflammatory pathways.
Inflammatory / Molecular Mechanisms
The displaced endometrial cells interact with adjacent myometrial cells, causing:
- Myometrial hypertrophy and enlargement of the uterus
- Local inflammation mediated by proinflammatory cytokines (similar to endometriosis: IL-1, IL-6, IL-8, TNF, PGE2, VEGF, MMPs)
Summary
The classic risk profile is a multiparous woman in her late 30s–40s with a history of uterine instrumentation, presenting with heavy and painful periods. The condition regresses after menopause, confirming its estrogen dependence.
Sources: Robbins, Cotran & Kumar Pathologic Basis of Disease; Robbins & Kumar Basic Pathology; Sabiston Textbook of Surgery; Tintinalli's Emergency Medicine
Risk factors for leiomyosarcoma
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
I have sufficient information from multiple authoritative sources. Here is a comprehensive answer:
Leiomyosarcoma — Risk Factors
Leiomyosarcoma (LMS) is a malignant smooth muscle tumor. It can arise from virtually any site containing smooth muscle — most commonly the uterus/retroperitoneum, and also soft tissues, vasculature, and skin.
1. Age & Sex
- Peak incidence in the 6th–7th decades of life
- Uterine and retroperitoneal LMS are more common in females
- Non-uterine sites (extremity, retroperitoneum excluding uterus) show a male predominance
- Cutaneous/subcutaneous LMS affects middle-aged to elderly adults, with a male-to-female ratio of ~5:1
2. Prior Radiation Exposure
- A well-established risk factor, particularly for radiation-induced sarcomas arising in previously irradiated fields
- Leiomyosarcoma may also rarely develop following trauma to superficial areas
3. Immunosuppression & Epstein-Barr Virus (EBV)
- Immunosuppression (e.g., in HIV/AIDS or post-transplant) combined with EBV infection is a recognized risk factor
- HIV-positive patients are susceptible to EBV-associated malignancies including LMS
- EBV-driven LMS is a distinct subset, particularly in immunocompromised individuals
4. Hereditary Syndromes
| Syndrome | Association |
|---|---|
| Hereditary retinoblastoma (RB1 germline mutation) | Increased risk of secondary uterine and soft-tissue LMS; RB1 locus alterations also found in sporadic LMS |
| Li-Fraumeni syndrome (TP53 mutation) | Predisposes to multiple sarcomas including LMS |
| Neurofibromatosis type 1 | Predisposes to peripheral nerve sheath tumors and other sarcomas |
| Gorlin syndrome | Associated with fibrosarcoma and LMS |
| Hereditary leiomyomatosis and renal cell cancer (HLRCC) (FH gene mutation) | Risk of uterine LMS; exact magnitude unclear |
5. Molecular/Genetic Factors
- TP53, RB, PTEN deletions/mutations are common acquired alterations in LMS — contributing to malignant transformation
- MED12 mutations: present in a subset of LMS (as in leiomyomas), suggesting a shared but divergent smooth muscle lineage
- LMS arises from the myometrium or endometrial stromal precursor cells — importantly, leiomyomas (fibroids) are NOT precursors to leiomyosarcoma; the two tumors arise independently
Key Distinguishing Point
Leiomyosarcoma is not a malignant transformation of a pre-existing leiomyoma. They have distinct cytogenetics and clinical behavior. Leiomyosarcomas tend to be solitary, postmenopausal (uterine), whereas leiomyomas are multiple and premenopausal.
Sources: Sabiston Textbook of Surgery; Robbins, Cotran & Kumar Pathologic Basis of Disease; Robbins & Kumar Basic Pathology; Fitzpatrick's Dermatology; Mulholland & Greenfield's Surgery
Causes for secondary and primary dysmenorrhoea
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I have comprehensive information from multiple authoritative sources. Here is the full answer:
Dysmenorrhoea — Primary vs Secondary: Causes
Definition
- Primary dysmenorrhoea: Painful menstruation without any underlying pelvic pathology
- Secondary dysmenorrhoea: Painful menstruation associated with an identifiable underlying pelvic pathology
Primary Dysmenorrhoea
Cause — Prostaglandin-Mediated Uterine Hypercontractility
There is no structural pathology. The mechanism is:
- Progesterone withdrawal in the late luteal phase triggers lytic enzymatic activity
- This releases phospholipids → arachidonic acid → COX pathway activation
- Excess prostaglandins (PGE₂, PGF₂α) and thromboxane are produced in the secretory endometrium
- These cause:
- Increased uterine tone with high-amplitude, dysrhythmic contractions
- Decreased uterine blood flow (ischaemia)
- Peripheral nerve hypersensitivity
Women with primary dysmenorrhoea have upregulated COX enzyme activity and prostanoid synthase activity compared to asymptomatic women.
Clinical Profile
- Onset within 1–2 years of menarche (once ovulatory cycles are established)
- Pain begins a few hours before or at the start of menstruation, lasting 48–72 hours
- Associated with: lumbosacral backache, nausea, vomiting, diarrhoea, and rarely syncope
- Normal pelvic examination and ultrasound
Secondary Dysmenorrhoea
Causes
Pain typically begins 1–2 weeks before menses and persists for a few days after bleeding stops — a broader pain window than primary dysmenorrhoea.
| Cause | Notes |
|---|---|
| Endometriosis | Most common cause; ectopic endometrial tissue responds to hormonal cycling; associated with dyspareunia, dyschezia, subfertility |
| Adenomyosis | Endometrial tissue within the myometrium; causes heavy, painful periods; enlarged boggy uterus |
| Uterine fibroids (leiomyomata) | Submucosal or intramural fibroids distort the cavity and increase uterine contractility |
| Endometrial polyps | Intracavitary lesions causing abnormal bleeding and cramping |
| Copper (non-hormonal) IUD | Increases local prostaglandin production in the endometrium |
| Pelvic inflammatory disease (PID) / subacute endometritis | Chronic infection causes pelvic inflammation and scarring |
| Cervical stenosis | Obstructs menstrual outflow, causing retrograde pressure and cramping |
| Congenital pelvic malformations | Outflow obstruction (e.g., imperforate hymen, uterine septum, bicornuate uterus) |
| Ovarian cysts | Functional or endometriotic cysts causing cyclic pelvic pain |
| Adhesions | Post-surgical or post-infectious pelvic adhesions restricting uterine mobility |
Most Common Causes (in order)
- Endometriosis
- Adenomyosis
- Non-hormonal (copper) IUD
Distinguishing Features at a Glance
| Feature | Primary | Secondary |
|---|---|---|
| Age of onset | Shortly after menarche | Years after menarche |
| Pelvic exam | Normal | Abnormal (often) |
| Pain timing | Onset at start of menses | Starts 1–2 weeks before menses |
| Ovulatory cycles required | Yes | Not necessarily |
| Response to NSAIDs | Good | Partial or poor |
Sources: Berek & Novak's Gynecology; Swanson's Family Medicine Review; Harrison's Principles of Internal Medicine
Endometriosis management types depending on features
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Excellent — I now have comprehensive, detailed content from Berek & Novak's Gynecology. Here is the full structured answer:
Endometriosis Management — by Clinical Feature
Treatment must be individualized based on the dominant clinical problem: pain, infertility, or both. The least invasive, least expensive, and most effective approach should be chosen (ESHRE guidelines).
1. Endometriosis with Pain (No Desire for Pregnancy)
Step 1 — First-Line Medical Therapy
Start here in women who are not actively trying to conceive and have no adnexal mass (avoid laparoscopy initially):
| Agent | Details |
|---|---|
| NSAIDs | For analgesia; target prostaglandin-mediated pain |
| Combined OCP (estrogen + progestin) | Both cyclic and continuous regimens effective; continuous OCP may be superior for pain control; first-line hormonal option |
Step 2 — Second-Line Medical Therapy
For refractory symptoms or contraindication to estrogen:
| Agent | Details |
|---|---|
| High-dose progestins | Medroxyprogesterone acetate (MPA), norethindrone acetate; dose to achieve amenorrhea, then taper; effective in ~75% |
| Levonorgestrel IUS (Mirena) | Comparable to depot GnRH for chronic pain |
| Etonogestrel implant | As effective as MPA |
| GnRH agonists (e.g., leuprolide) | With add-back therapy (norethindrone acetate ± low-dose oestrogen + calcium) to limit hypoestrogenic side effects; typically used ≤6–12 months; with add-back may extend beyond 1 year |
| Danazol | Suppresses LH surge and steroidogenesis; androgenic side effects (acne, weight gain, hirsutism, voice changes) limit use; vaginal danazol at lower dose may be preferred |
| Aromatase inhibitors (anastrozole, letrozole) | Combined with OCP, progestin, or GnRH agonist (to prevent ovarian cysts in premenopausal women); reduces pain and lesion size; promising but limited evidence |
| GnRH antagonists (elagolix — oral) | Dose-dependent oestrogen suppression; immediate onset unlike agonists; no initial flare |
2. Endometriosis with Pain — Surgical Management
Indicated when: medical therapy fails, adnexal mass is present, or diagnosis is uncertain.
Laparoscopy is preferred over laparotomy (equally effective, faster recovery, fewer adhesions, lower morbidity). Laparotomy reserved for rare advanced disease where laparoscopy is impossible.
Peritoneal Endometriosis
- Excision (scissors), bipolar coagulation, or laser ablation (CO₂, KTP, argon)
- Diagnosis and removal should occur simultaneously at the same laparoscopy (with preoperative consent)
Ovarian Endometriomas
- Cystectomy (excision of cyst wall) preferred over drainage/ablation — reduces recurrence and improves pain
- Caution: cystectomy may reduce ovarian reserve (↓ AMH, ↓ antral follicle count)
Deep Infiltrating Endometriosis (DIE)
- Most complex; referral to specialist centre recommended
- Preoperative 3-month medical therapy (GnRH agonist or progestin) is common practice to reduce inflammation and vascularity before surgery
- Complete excision is the goal
Adhesiolysis
- Excision of endometriosis-related pelvic adhesions to restore normal anatomy
- Adhesion barriers (oxidised regenerated cellulose) may be considered but not routinely recommended
Nerve Pathway Interruption
- Presacral neurectomy (PSN): effective add-on for midline pain; requires expertise; risks include bleeding, constipation, urinary urgency
- LUNA: no additional benefit over excision alone — not recommended
Definitive Surgery (Hysterectomy ± BSO)
- For women who have completed childbearing and failed all other treatments
- Bilateral salpingo-oophorectomy eliminates oestrogen drive; risk of surgical menopause must be discussed
3. Endometriosis with Infertility (No Active Pain Management Priority)
| Stage | Approach |
|---|---|
| Mild–moderate (Stage I–II) | Laparoscopic excision/ablation of peritoneal lesions improves spontaneous pregnancy rates |
| Moderate–severe (Stage III–IV) | Surgery to restore pelvic anatomy; pregnancy rates 24–30% at 9–12 months post-surgery |
| Ovarian endometrioma | Cystectomy preferred over ablation — increases postoperative spontaneous pregnancy rates and ovarian follicular response to stimulation |
| Refractory / failed surgery | ART (IVF/ICSI) — bypasses anatomical distortion; indicated when other treatments fail |
Key note: Postoperative hormonal suppression does not improve fertility outcomes — it only delays natural conception attempts. Medical therapy does not treat infertility.
4. Endometriosis in Adolescents
- Multidimensional approach: NSAIDs + OCP first
- Laparoscopy indicated if medical therapy fails (NSAIDs + OCP with 3–6 month trial)
- Combined: hormonal manipulation, pain clinic, psychological support, complementary therapies, self-management education
5. Extragenital / Deep Endometriosis
- Complete surgical excision is the treatment of choice when feasible
- When complete excision is not possible, long-term medical treatment using same principles as pelvic endometriosis
6. Recurrent Endometriosis
- Recurrence is expected — hormonal suppression only suppresses activity, does not cure
- Recurrence after GnRH agonist: 36–70% within 5 years
- Options: repeat surgery, long-term hormonal suppression, or ART for fertility
Source: Berek & Novak's Gynecology (ESHRE guideline-based); Harrison's Principles of Internal Medicine 22e
Regarding HRT after hysterectomy with bilateral salpingo oophorectomy and other indicators for HCT in a women
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have excellent content from multiple authoritative sources. Here is the comprehensive answer:
HRT After Hysterectomy + Bilateral Salpingo-Oophorectomy (BSO)
Surgical Menopause vs Natural Menopause
Hysterectomy with BSO causes surgical menopause — critically different from natural menopause:
| Feature | Natural Menopause | Surgical Menopause (post-BSO) |
|---|---|---|
| Onset | Gradual, over years | Abrupt |
| Oestrogen decline | Variable, slow | Sudden, steep |
| FSH rise | Gradual | Abrupt, sharp |
| Ovarian androgen production | Continues (→ converts to oestrone) | Lost |
| Severity of symptoms | Milder due to adaptation | Often more severe |
In natural menopause, residual ovaries continue secreting androgens (testosterone, androstenedione) which convert peripherally to oestrone. This buffer is absent after BSO, making HRT particularly important.
HRT Regimen After Hysterectomy + BSO
Key Principle: Oestrogen-Only HRT
Because the uterus has been removed, there is no endometrium at risk of hyperplasia or carcinoma. Therefore:
Progestogen is NOT required and should be omitted — avoiding its potential adverse effects (mood changes, breast cancer risk, metabolic effects).
Women who retain their uterus need combined oestrogen + progestogen to protect the endometrium. Women post-hysterectomy need oestrogen alone.
Preferred Route: Transdermal (patch, gel, or spray)
- Avoids first-pass hepatic metabolism
- Lower VTE risk compared to oral oestrogen
- Recommended particularly if VTE risk is elevated (obesity, personal/family history)
- Oral oestrogen increases SHBG, angiotensinogen, and may affect bile cholesterol
Regimen Options
| Route | Formulation |
|---|---|
| Transdermal patch | 25–100 mcg twice weekly |
| Oestradiol gel | 0.6–1.5 mg daily (1–4 pumps) |
| Oestradiol spray | 1.53 mg/spray, 1–3 sprays daily |
| Oral | Conjugated equine oestrogen or oestradiol (higher VTE risk) |
Dose: Use the lowest effective dose to control symptoms; titrate empirically.
Indications for HRT in Women (General)
1. Vasomotor Symptoms (Hot Flushes / Night Sweats)
- Commonest and primary indication
- HRT is the most effective treatment — first-line pharmacological option
- Benefits all menopausal women; especially important post-BSO where symptoms are abrupt and severe
- Alternatives when HRT is contraindicated: SSRIs/SNRIs (paroxetine best studied), clonidine, gabapentin
2. Surgical Menopause / Premature Ovarian Insufficiency (POI)
- Women who undergo BSO before natural menopause age (~51 years) are at increased risk of:
- Cardiovascular disease
- Osteoporosis
- Cognitive impairment / dementia / parkinsonism
- Depression and anxiety
- Sexual dysfunction
- All-cause mortality
- HRT mitigates many of these risks and should be used until at least the natural age of menopause
3. Osteoporosis Prevention and Treatment
- Oestrogen decreases bone resorption — most effective agent for preventing fractures at all skeletal sites
- Most effective when started before significant bone loss
- Effect requires continuous use; bone loss resumes on cessation
- Adjunct: adequate calcium, vitamin D, weight-bearing exercise
- First-line for osteoporosis prevention in younger surgical menopause; bisphosphonates considered first-line in older postmenopausal women
4. Urogenital Atrophy (Genitourinary Syndrome of Menopause)
- Vaginal dryness, dyspareunia, urinary urgency/frequency, recurrent UTIs
- Local (vaginal) oestrogen preferred when symptoms are confined to urogenital tract — minimal systemic absorption, safe even in many women with contraindications to systemic HRT
- Systemic HRT also effective
5. Premature Ovarian Failure / Primary Hypogonadism
- Replacement therapy to develop secondary sex characteristics and maintain bone/cardiovascular health
- Combined oestrogen + progestogen in those with an intact uterus; oestrogen-only post-hysterectomy
6. Perimenopausal Depression / Mood Disturbance
- Menopausal transition confers 2–4× increased risk of depressive symptoms
- HRT may improve mood, particularly linked to oestradiol fluctuation
- Not a standalone psychiatric treatment but supportive
7. Cardiovascular Risk Modification
- Favourable lipid profile: ↑ HDL, ↓ LDL (more with oral than transdermal)
- Vasodilatory and anti-atherosclerotic effects
- Best cardiovascular benefit when started early (within 10 years of menopause / before age 60) — the "timing hypothesis"
- Oral combined HRT in older women initially increased cardiac events; transdermal preferred in those with cardiovascular risk
Contraindications to HRT
| Absolute | Precautions |
|---|---|
| Oestrogen-dependent malignancies (breast, endometrial cancer) | Symptomatic fibroids |
| Undiagnosed vaginal bleeding | Untreated hypertension |
| Active liver disease with abnormal LFTs | Migraine with aura (VTE risk) |
| Active or recent thromboembolic disease (VTE, MI, angina) | History of VTE/stroke → use transdermal |
| Untreated endometrial hyperplasia | Endometriosis — carefully choose progestogen-sparing regimen |
| Pregnancy | Epilepsy (lamotrigine interaction) |
Special Case: HRT After Hysterectomy + BSO for Endometriosis
- Risk of reactivating residual endometriotic tissue with oestrogen-only HRT is small but present
- A systematic review found only 17 reported cases of recurrence with post-BSO HRT
- Consider tibolone or combined oestrogen + progestogen (despite no uterus) if there is concern about residual implants
- Weigh against risks of untreated surgical menopause — HRT is generally recommended
Sources: Maudsley Prescribing Guidelines in Psychiatry 15e; Goodman & Gilman's Pharmacological Basis of Therapeutics; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Lippincott Illustrated Reviews — Pharmacology; Berek & Novak's Gynecology
This is a shared conversation. Sign in to Orris to start your own chat.